Antibodies to type II collagen (CII) cause articular damage in collagen-induced arthritis (CIA) in mice as judged by passive transfer to naive animals of mAb to CII. We tested the hypothesis that mAb degrade cartilage structure by reacting with functionally important regions of the collagen molecule by examining the effects of an arthritogenic mAb to CII, CII-C1, on cultured bovine chondrocytes at high density, at days 7 and 14. The effects were compared of CII-C1, an isotype-matched control mAb, or medium alone, on chondrocyte proliferation and viability, cell morphology, matrix structure by light and electron microscopy, and matrix synthesis by metabolic labelling with 3H-proline for collagen or 35SO4 for proteoglycans. Chondrocytes in culture remained viable, proliferated, and produced an extracellular matrix in which CII was the major collagen. The addition of CII-C1, but not a control mAb, increased the synthesis of CII and proteoglycan, and caused disorganization of the extracellular matrix and thin collagen fibrils ultrastructurally. Moreover, using a cell-free assay, CII-C1 inhibited the normal self-assembly of collagen fibrils from CII in solution. The finding that the mAb to CII, CII-C1 has striking degradative effects in vitro on cartilage synthesis suggests that antibodies to collagen perpetuate the chronic phase of CIA and that, in mice at least, such antibodies are an important component of pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.0818-9641.2004.01267.xDOI Listing

Publication Analysis

Top Keywords

mab cii
12
collagen
8
type collagen
8
cia mice
8
cii cii-c1
8
control mab
8
extracellular matrix
8
collagen fibrils
8
cii
7
cii-c1
6

Similar Publications

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma.

Cancer Immunol Immunother

October 2024

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.

Patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) show varied responses to PD-1 monoclonal antibody (mAb) containing regimens. The mechanisms and predictive biomarkers for the efficacy of this regimen are unclear. This study retrospectively collected r/r DLBCL patients who received PD-1 mAb and rituximab regimens as salvage therapy.

View Article and Find Full Text PDF

Background: The efficacy of antibody-targeted therapy of solid cancers is limited by the lack of consistent tumour-associated antigen expression. However, tumour-associated antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies, or by chimeric antigen receptor (CAR) T cells or CAR NK cells activated either by the tumour microenvironment or following 'unlocking' via multiple antigen-recognition. In this study, we have focused on tissue factor (TF; CD142), a type I membrane protein present on a range of solid tumours as a basis for future development of conditionally-activated BiTE or CAR T cells.

View Article and Find Full Text PDF
Article Synopsis
  • Adoptive cellular therapy (ACT) using memory-like natural killer (NK) cells activated with specific cytokines shows promise in treating blood cancers, especially when combined with new fusion molecules.
  • The multifunctional fusion molecule HCW9206 improves the expansion of NK cells that have been primed with another molecule (HCW9201), leading to a significant increase in their quantity and activity.
  • The "Prime and Expand" strategy enhances NK cell metabolism and durability, making it a more efficient method for preparing clinical-grade NK cells for future cancer treatments.
View Article and Find Full Text PDF

Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.

Cancer Immunol Immunother

March 2024

Department of Hepatobiliary Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.

How to increase the response of immune checkpoint inhibitors (ICIs) is a challenge. In clinical, we found that Zoledronic acid (ZA) may increase the anti-tumor effect of immunotherapy for hepatocellular carcinoma (HCC). To explore the underlying mechanism, we established a mouse model of HCC by subcutaneously injecting Hepa1-6 cell line.

View Article and Find Full Text PDF
Article Synopsis
  • Over the last decade, FDA-approved immune checkpoint inhibitors, particularly targeting PD-1, have shown promising clinical benefits, especially for patients with PD-L1 expressing tumors, with toripalimab specifically approved for treating nasopharyngeal carcinoma alongside chemotherapy.
  • In phase 3 studies, toripalimab demonstrated improved overall survival across various cancers, including nasopharyngeal carcinoma and advanced lung and esophageal cancers, regardless of PD-L1 status.
  • Research indicates that toripalimab has a significantly higher affinity for PD-1 compared to pembrolizumab, enhances immune responses, and shows unique activation patterns in tumor environments, highlighting its potential as a powerful anti-cancer treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!